Affiliations 

  • 1 Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
  • 2 Health Economics and Epidemiology Research Office, Johannesburg, South Africa
  • 3 FIND, Geneva, Switzerland
  • 4 Clinical Research Center, Hospital Sultanah Bahiyah, Alor Setar, Malaysia
  • 5 Lugar Research Center, National Center for Disease Control and Public Health, Tbilisi, Georgia
  • 6 LIFEMED, Pelotas, Brazil
  • 7 Secretaria Municipal de Saúde, Afogados da Ingazeira, Brazil
  • 8 KNCV Tuberculosis Foundation, Addis Ababa, Ethiopia
  • 9 KNCV Tuberculosis Foundation, Manila, Philippines
  • 10 The Aurum Institute for Health Research, Accra, Ghana
  • 11 KNCV Tuberculosis Foundation, Den Haag, The Netherlands
  • 12 WHO, Geneva, Switzerland
  • 13 Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands brooke.nichols@finddx.org
BMJ Open, 2024 Apr 17;14(4):e078852.
PMID: 38631825 DOI: 10.1136/bmjopen-2023-078852

Abstract

OBJECTIVE: Diagnostic testing is an important tool to combat the COVID-19 pandemic, yet access to and uptake of testing vary widely 3 years into the pandemic. The WHO recommends the use of COVID-19 self-testing as an option to help expand testing access. We aimed to calculate the cost of providing COVID-19 self-testing across countries and distribution modalities.

DESIGN: We estimated economic costs from the provider perspective to calculate the total cost and the cost per self-test kit distributed for three scenarios that differed by costing period (pilot, annual), the number of tests distributed (actual, planned, scaled assuming an epidemic peak) and self-test kit costs (pilot purchase price, 50% reduction).

SETTING: We used data collected between August and December 2022 in Brazil, Georgia, Malaysia, Ethiopia and the Philippines from pilot implementation studies designed to provide COVID-19 self-tests in a variety of settings-namely, workplace and healthcare facilities.

RESULTS: Across all five countries, 173 000 kits were distributed during pilot implementation with the cost/test distributed ranging from $2.44 to $12.78. The cost/self-test kit distributed was lowest in the scenario that assumed implementation over a longer period (year), with higher test demand (peak) and a test kit price reduction of 50% ($1.04-3.07). Across all countries and scenarios, test procurement occupied the greatest proportion of costs: 58-87% for countries with off-site self-testing (outside the workplace, for example, home) and 15-50% for countries with on-site self-testing (at the workplace). Staffing was the next key cost driver, particularly for distribution modalities that had on-site self-testing (29-35%) versus off-site self-testing (7-27%).

CONCLUSIONS: Our results indicate that it is likely to cost between $2.44 and $12.78 per test to distribute COVID-19 self-tests across common settings in five heterogeneous countries. Cost-effectiveness analyses using these results will allow policymakers to make informed decisions on optimally scaling up COVID-19 self-test distribution programmes across diverse settings and evolving needs.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.